Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baricitinib for chronic tophaceous gouty arthritis
ChiCTR2300069207Phase 4Recruiting
- Sponsor
- Huashan Hospital
- Start
- Dec 2022
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4 trial of baricitinib in chronic gout and gout (2 arms), sponsored by Huashan Hospital. Primary endpoints: Gouty radiology bone erosion (target joint) and Incidence of adverse events and serious adverse events. Started Dec 2022; status: recruiting.
02
Drugs
baricitinib
03
Conditions
chronic goutgout
Beyond the preview
Go deeper on ChiCTR2300069207.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300069207.